Memphis Pharmaceuticals (MPCI)

Memphis Pharmaceuticals & Chemical Industries engages in the research, development, manufacture, marketing, and distribution of pharmaceutical products for human and veterinary use in Egypt and internationally. The company offers human health products in various therapeutic areas, including anti-infective, central nervous system, dermatological, cardiovascular diseases, vitamins and minerals, analgesics and antipyretics, respiratory system, and gastrointestinal and metabolic disorders. It also provides products for anthelmintic, anti-hypertensive angiotensin blockers, anti-dandruff, antifungal, antihistamine, anti-pyretic, anti-spasmodic, antigout, anti-tuberculosis, anxiolytics and antipsychotic, antitussive, calcium deficiency treatment, cold and flu, emergency injection, folic acid deficiency treatment, gastric-enteritis pre-surgical, heart burn, immunity enhancer, injectable and oral corticosteroids, laxative, local anesthetic, local treatment vitiligo, loop diuretic, muscle relaxant, narcotic opioid, NSAID, oral and topical antibiotics, antiemetic, peptic ulcer proton pump inhibitor, prolactin inhibitor, local treatment psoriasis, topical anti-inflammatory, topical moisturizing, migraine, and urinary incontinence antispasmodics, as well as vitamin b, c, d, and k deficiency treatment. In addition, the company offers veterinary health products in powder, oral solution, and injection forms; cosmetics; and veterinary additives, including feed supplements and other additives. It exports its products to approximately 30 countries, including Somalia, Tunisia, Libya, Uganda, Eritrea, Kuwait, Yemen, Jordan, Mali, Senegal, and South Korea. The company was founded in 1940 and is headquartered in Cairo, Egypt. Memphis Pharmaceuticals & Chemical Industries is a subsidiary of HoldiPharma.